Nightingale Health, a Finnish disease risk detection company listed on Nasdaq Helsinki (HEALTH), has entered an agreement with Barnes Private Practice, a private GP practice in south-west London, to provide the Nightingale Health Check within its annual health assessments. The test gives patients a 10-year risk estimate for five common chronic diseases from a single blood sample, with the service starting in November 2026.

Under the agreement, Barnes Private Practice offers the test to its patients and Nightingale Health analyses the blood samples.

The test estimates 10-year risk of heart attack, ischemic stroke, type 2 diabetes, chronic kidney disease and fatty liver disease, and the report also includes the person’s Metabolic Age and Metabolic Resilience Score.

Barnes Private Practice, at 22 Castelnau, Barnes, is led by Dr Alain Palacci and Dr Alexandra Strachan and is part of HCA Healthcare UK, with visiting consultants in cardiology, urology, dietetics, dermatology and physiotherapy. Patients needing further specialist care can be referred to HCA Healthcare UK’s hospitals in central London.

“Prevention has always been at the heart of how we practise,” said Dr Alain Palacci and Dr Alexandra Strachan, GPs at Barnes Private Practice. “A routine blood test tells us how someone’s values look today. The Nightingale Health Check tells us, from the same sample, how their risks are likely to develop over the next ten years, so we can plan with each patient, and with our visiting consultants where needed, what to do about them.”

Teemu Suna, CEO and founder of Nightingale Health, said patients’ “own doctor can act on the results”. “This agreement continues our growth in private primary care in the United Kingdom,” Suna added.

Nightingale Health reported revenue of €5.5 million for its 2025-26 financial year, up 17 percent, with an EBITDA loss of €13.99 million, and is targeting at least €10 million of revenue this year.

The structural driver is prevention, with chronic conditions such as heart disease and type 2 diabetes developing quietly for years before a patient feels anything.

For the sector, the agreement shows private GP practices adding blood-based risk prediction to annual assessments as a preventive care offer.